Genomtec SA (GMT) Stock Statistics & Valuation Metrics
Total Valuation
Genomtec SA has a market cap or net worth of PLN 41.72M. The enterprise value is PLN 63.76M.
- Market Cap
- PLN 41.72M
- Enterprise Value
- PLN 63.76M
Share Statistics
Genomtec SA has 17,064,634 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 17,064,634
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Genomtec SA’s return on equity (ROE) is -1.13 and return on invested capital (ROIC) is -115.06%.
- Return on Equity (ROE)
- -1.13
- Return on Assets (ROA)
- -0.68
- Return on Invested Capital (ROIC)
- -115.06%
- Return on Capital Employed (ROCE)
- -1.31
- Revenue Per Employee
- 656.25
- Profits Per Employee
- -325.97K
- Employee Count
- 32
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Genomtec SA is -4.59. Genomtec SA’s PEG ratio is -0.09.
- PE Ratio
- -4.59
- PS Ratio
- 1113.81
- PB Ratio
- 2.63
- Price to FCF
- -7.65
- Price to Operating Cash Flow
- -7.77
- PEG Ratio
- -0.09
Income Statement
In the last 12 months, Genomtec SA had revenue of 21.00K and earned -10.43M in profits. Earnings per share was -0.69.
- Revenue
- 21.00K
- Gross Profit
- -2.78M
- Operating Income
- -14.78M
- Pretax Income
- -10.46M
- Net Income
- -10.43M
- EBITDA
- -11.98M
- Earnings Per Share (EPS)
- -0.69
Cash Flow
In the last 12 months, operating cash flow was -5.31M and capital expenditures -80,000, giving a free cash flow of -5.39M billion.
- Operating Cash Flow
- -5.31M
- Free Cash Flow
- -5.39M
- Free Cash Flow per Share
- -0.32
Dividends & Yields
Genomtec SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -13.07%
- Earnings Yield
- -19.76%
Stock Price Statistics
- Beta
- -0.17
- 52-Week Price Change
- -50.10%
- 50-Day Moving Average
- 3.17
- 200-Day Moving Average
- 4.34
- Relative Strength Index (RSI)
- 27.90
- Average Volume (3m)
- 24.85K
Important Dates
Genomtec SA upcoming earnings date is Nov 27, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Oct 05, 2026
- Next Earnings Date
- Nov 27, 2026
- Ex-Dividend Date
- ―
Financial Position
Genomtec SA as a current ratio of 2.26, with Debt / Equity ratio of 19.77%
- Current Ratio
- 2.26
- Quick Ratio
- 2.26
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.24
- Interest Coverage Ratio
- -48.29
Taxes
In the past 12 months, Genomtec SA has paid -33.00K in taxes.
- Income Tax
- -33.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Genomtec SA EV to EBITDA ratio is -2.56, with an EV/FCF ratio of -5.29.
- EV to Sales
- 770.81
- EV to EBITDA
- -2.56
- EV to Free Cash Flow
- -5.29
- EV to Operating Cash Flow
- -5.37
Balance Sheet
Genomtec SA has PLN 14.24M in cash and marketable securities with PLN 1.55M in debt, giving a net cash position of PLN 12.69M billion.
- Cash & Marketable Securities
- PLN 14.24M
- Total Debt
- PLN 1.55M
- Net Cash
- PLN 12.69M
- Net Cash Per Share
- PLN 0.74
- Tangible Book Value Per Share
- PLN 0.78
Margins
Gross margin is -20970.27%, with operating margin of -37524.32%, and net profit margin of -22008.11%.
- Gross Margin
- -20970.27%
- Operating Margin
- -37524.32%
- Pretax Margin
- -22054.05%
- Net Profit Margin
- -22008.11%
- EBITDA Margin
- -30162.16%
- EBIT Margin
- -37556.76%
Analyst Forecast
The average price target for Genomtec SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- 236.36%
- EPS Growth Forecast
- 36.73%
